- Home
- BAK vs OCS Comparison
BAK vs OCS Comparison
Compare BAK & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAK
- OCS
- Stock Information
- Founded
- BAK 1972
- OCS 2003
- Country
- BAK Brazil
- OCS Switzerland
- Employees
- BAK N/A
- OCS N/A
- Industry
- BAK Major Chemicals
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- BAK Industrials
- OCS Health Care
- Exchange
- BAK Nasdaq
- OCS Nasdaq
- Market Cap
- BAK 952.4M
- OCS 869.8M
- IPO Year
- BAK N/A
- OCS N/A
- Fundamental
- Price
- BAK $2.59
- OCS $21.01
- Analyst Decision
- BAK Hold
- OCS Strong Buy
- Analyst Count
- BAK 2
- OCS 4
- Target Price
- BAK $4.40
- OCS $41.00
- AVG Volume (30 Days)
- BAK 998.7K
- OCS 85.4K
- Earning Date
- BAK 11-10-2025
- OCS 11-06-2025
- Dividend Yield
- BAK N/A
- OCS N/A
- EPS Growth
- BAK N/A
- OCS N/A
- EPS
- BAK N/A
- OCS N/A
- Revenue
- BAK $14,266,076,929.00
- OCS $960,668.00
- Revenue This Year
- BAK $2.44
- OCS $38.85
- Revenue Next Year
- BAK $9.90
- OCS $994.06
- P/E Ratio
- BAK N/A
- OCS N/A
- Revenue Growth
- BAK 10.48
- OCS N/A
- 52 Week Low
- BAK $2.32
- OCS $14.00
- 52 Week High
- BAK $6.34
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- BAK 46.39
- OCS 57.70
- Support Level
- BAK $2.58
- OCS $20.91
- Resistance Level
- BAK $2.77
- OCS $21.84
- Average True Range (ATR)
- BAK 0.10
- OCS 0.64
- MACD
- BAK 0.04
- OCS -0.11
- Stochastic Oscillator
- BAK 60.00
- OCS 28.78
About BAK Braskem SA ADR
Braskem SA manufactures and sells chemicals, petrochemicals, fuels, and utilities. The company's geographical segments include Brazil; the United States and Europe and Mexico. It derives a majority of its revenue from Brazil. It produces olefins, such as ethylene, polymer and chemical-grade propylene, butadiene, and butene-1; fuels, such as automotive gasoline, liquefied petroleum gas, or LPG, ethyl tertiary-butyl ether, or ETBE, and methyl tertiary-butyl ether, or MTBE; intermediates, such as cumene and others.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.